Skip to main content

Table 2 Costs and health outcomes of the cost effectiveness model for two screening strategies

From: Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore

Strategy

Lifetime costs per case (SGD)

Life Years

Quality- Adjusted Life Years (QALYs)

Incremental Calculations (Tailored – Current)

Costs

Life Years

QALYs

ICER (SGD/QALY)

Current mammogram only screening

23,729.57

21.89

21.80

–

–

–

–

Polygenic Risk Tailored Screening (60th low, 35th int, 5th high)

20,058.74

22.86

22.79

-3670.83

0.9720

0.9884

-3713.80

Scenario Analysis

 60th low, 30th int, 10th high

21,474.94

22.86

22.78

-2254.63

0.9686

0.9800

-2300.45

 40th low, 55th int, 5th high

22,242.34

22.85

22.77

-1487.23

0.9599

0.9681

-1536.20

 40th low, 50th int, 10th high

23,658.54

22.85

22.76

−71.02

0.9566

0.9598

−74.00

  1. Summary of cost and health outcomes of the cost-effectiveness analysis, in terms of costs, life years, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). The strategies being compared are the current mammogram-only screening strategy and a proposed polygenic risk-tailored screening strategy. The base polygenic risk-tailored screening strategy was cheaper by SGD -3670.83, with a QALY gain per woman of 0.9884, giving a negative ICER of −3713,80 SGD/QALY over the age-based mammogram-only programme. Scenario analysis compared three scenarios (60 L-30I-10H, 40 L-55I-05H, 40 L-50I-10H) with different polygenic risk cutoffs in percentiles for polygenic risk tailored screening, and for all three scenarios, the ICER was negative (−2300.45 SGD/QALY, −1536.20 SGD/QALY, − 74.00 SGD/QALY)